cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cerus Europe ...
IRS number
680262011
CERS stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Cerus Corporation Announces First Quarter 2024 Financial Results
2 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
8-K
Other Events
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
8-K
Year 2023 Product Revenue and Provides Business Update
8 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
Transcripts
CERS
Earnings call transcript
2024 Q1
2 May 24
CERS
Earnings call transcript
2023 Q4
5 Mar 24
CERS
Earnings call transcript
2023 Q3
2 Nov 23
CERS
Earnings call transcript
2023 Q2
2 Aug 23
CERS
Earnings call transcript
2023 Q2
2 Aug 23
CERS
Earnings call transcript
2023 Q1
4 May 23
CERS
Earnings call transcript
2022 Q4
28 Feb 23
CERS
Earnings call transcript
2022 Q3
3 Nov 22
CERS
Earnings call transcript
2022 Q2
4 Aug 22
CERS
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm |
Cash burn (monthly) | 1.09 mm | 976.17 k | 2.40 mm | 4.11 mm | 3.50 mm | 2.48 mm |
Cash used (since last report) | 8.30 mm | 7.44 mm | 18.31 mm | 31.35 mm | 26.65 mm | 18.89 mm |
Cash remaining | 10.85 mm | 11.72 mm | 847.09 k | -12.19 mm | -7.49 mm | 269.76 k |
Runway (months of cash) | 10.0 | 12.0 | 0.4 | -3.0 | -2.1 | 0.1 |
Institutional ownership, Q4 2023
22.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 2 |
Closed positions | 131 |
Increased positions | 5 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 47.84 bn |
Total shares | 41.40 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 20.91 mm | $45.17 bn |
Baker Bros. Advisors | 19.08 mm | $26.72 mm |
Assenagon Asset Management | 539.63 k | $1.17 bn |
Raymond James & Associates | 362.27 k | $782.50 mm |
Bouvel Investment Partners | 257.63 k | $556.47 mm |
SG Americas Securities | 188.70 k | $408.00 k |
Stratos Wealth Partners | 16.72 k | $36.11 mm |
Aprio Wealth Management | 15.00 k | $32.40 mm |
JGP Global Gestao de Recursos Ltda. | 14.23 k | $30.74 mm |
J Arnold Wealth Management | 13.33 k | $28.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 May 24 | Hua Shan | Common Stock | Buy | Acquire P | No | No | 1.9899 | 2,500 | 4.97 k | 32,386 |
10 May 24 | Jami K Nachtsheim | Common Stock | Buy | Acquire P | No | No | 1.7891 | 2,000 | 3.58 k | 108,362 |
9 May 24 | Daniel N Swisher JR | Common Stock | Buy | Acquire P | No | No | 1.8755 | 2,500 | 4.69 k | 107,045 |
9 May 24 | Witney Frank | Common Stock | Buy | Acquire P | No | No | 1.89 | 20,000 | 37.80 k | 180,059 |
14 Mar 24 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 1.9744 | 17,738 | 35.02 k | 459,612 |
13 Mar 24 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 17,377 | 35.74 k | 477,350 |
12 Mar 24 | Benjamin Richard J | Common Stock | Option exercise | Acquire M | No | No | 0 | 16,666 | 0.00 | 494,727 |
12 Mar 24 | Benjamin Richard J | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 16,666 | 0.00 | 0 |
News
Zomedica And 3 Other Stocks Under $3 Insiders Are Buying
14 May 24
ESS Tech And 2 Other Stocks Under $5 Insiders Are Buying
10 May 24
Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
3 May 24
Craig-Hallum Initiates Coverage On Cerus with Buy Rating, Announces Price Target of $5
12 Apr 24
Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session
8 Apr 24
Press releases
Cerus Corporation Announces First Quarter 2024 Financial Results
2 May 24
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
26 Mar 24
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24